Waldencast Acquisition Corp. a skin care company, provides advanced skin care treatments. Its products are designed to help minimize the appearance of premature skin aging, skin damage, hyperpigmentation, acne, and sun damage primarily available through dermatologists, plastic surgeons, medical spas, and other skin care professionals. Its portfolio includes Obagi Medical that provides transformational skin care products formulated to minimize signs of skin aging, address dark spots, hyperpigmentation, fine lines, and wrinkles and to protect and enhance skin tone and texture; and Obagi Clinical that offers skin care products designed to prevent the early signs of skin aging. The company was founded in 1988 and is based in White Plains, New York.

Waldencast plc

Waldencast is a self-described global beauty and wellness multi-brand platform.

Waldencast

Waldencast is a holding company and investment fund that incubates and accelerates early stage beauty and wellness brands and helps them rapidly create scale and profitability via industry specific operational expertise. Waldencast invests in brand-led business models and goes beyond traditional incubation and acceleration to develop a collective of innovative and unique brands that place responsible entrepreneurship at the heart of its operations.  Waldencast has offices in New York and London and has an investment portfolio in North America, Europe, and Latin America.

The selection of brands to participate in the community is as much driven by the strength of the brand concept and business model as it is by our shared human and social values: sustainability, responsibility, inclusivity.  We believe brands that marry purpose, art, beauty, and design with industry and commerce to make the planet and the lives of those in it better.

Individuals that are part of the Waldencast collective are as much driven by the strength of the brands’ ideas, as it is by sharing our dreamer/maker values: ambition with humility, idealism with practicality, grit with empathy, vision with action.

We have the spirit of a challenger, a disruptor, a game-changer. We are a start-up and we intend to stay in the attitude of a start-up regardless of our success.

Costa Brazil

2024 AWARD WINNING BROW SERUM🎉

InStyle has recognized Obagi Nu-Cil™ Eyebrow Boosting Serum as the Best Brow Serum in their Best Beauty Buys 2024 product roundup! 

“I was introduced to this powerhouse brow serum by board-certified dermatologist Mona Gohara, M.D.  …So it's safe to say I'm hooked.” writes Kara Jillian Brown

Thank you to our Obagi Fam and healthcare providers for the continuous love you show our products.

Visit your Obagi provider to learn more about this great product! 
#obagi #obagimedical #obagiskincare

Read the full article here:
https://lnkd.in/giiJuG-M

We're #hiring a new Amazon Brand Manager in Greater London, England. Apply today or share this post with your network.

Congratulations to our portfolio company C16 Biosciences for this recognition!

We are excited to participate in TD Cowen’s 8th annual conference 2024 with Oliver Chen, CFA and Jonna Kim, CFA.

We’re #hiring a new Glaze North America Key Account Director in United States. Apply today or share this post with your network.

	Mar '21	Jun '21	Sep '21	Dec '21	Mar '22	Jul '22	Sep '22	Dec '22	Dec '23	Mar '24
revenue							76.28M -	89.85M 17.80%	54.40M -	68.30M 25.55%
cost of revenue							40.50M -	86.20M 112.83%	17.70M -	18.70M 5.64%
gross profit							35.78M -	3.66M 89.78%	36.70M -	49.60M 35.16%
selling and marketing expenses
general and administrative expenses	117.52K -	201.57K 71.52%	645.12K 220.05%	8.17M 1,166.24%	4.00M 50.99%	4.40M 9.84%
selling general and administrative expenses	117.52K -	201.57K 71.52%	645.12K 220.05%	8.17M 1,166.24%	4.00M 50.99%	4.40M 9.84%	45.59M 936.67%	55.31M 21.33%	59.81M -
research and development expenses							1.74M -	2.67M 53.72%	237.50K -
other expenses	-719.20K -
cost and expenses	117.52K -	201.57K 71.52%	645.12K 220.05%	8.17M 1,166.24%	4.00M 50.99%	4.40M 9.84%	87.82M 1,897.10%	144.18M 64.17%	85.20M -	18.70M 78.05%
operating expenses	117.52K -	201.57K 71.52%	645.12K 220.05%	8.17M 1,166.24%	4.00M 50.99%	4.40M 9.84%	47.32M 976.13%	57.98M 22.52%	67.50M -
interest expense							3.27M -	9.61M 193.46%
ebitda	950.35K -	1.16M 22.25%	-9.03M 877.33%	3.13M 134.70%	-11.03M 451.87%	-11.30M 2.53%	471K 104.17%	-31.17M 6,717.20%	-9.24M -	64.48M 797.73%
operating income	-117.52K -	-201.57K 71.52%	-645.12K 220.05%	-8.17M 1,166.24%	-4.00M 50.99%	-4.40M 9.84%	-11.54M 162.51%	-54.32M 370.58%	-23.35M -	49.60M 312.40%
depreciation and amortization	1.07M -	1.36M 27.67%	-8.39M 715.09%	11.30M 234.78%	-7.02M 162.13%	-6.91M 1.64%	12.02M 273.95%	23.16M 92.73%	14.11M -	14.88M 5.49%
total other income expenses net	-1.07M -	-1.36M 27.67%	8.39M 715.09%	-11.30M 234.78%	7.02M 162.13%	6.91M 1.64%	-2.57M 137.19%	-84.66M 3,195.33%	-12.47M -	-49.60M 297.60%
income before tax	-1.18M -	-1.55M 31.04%	7.76M 599.99%	-19.45M 350.72%	3.02M 115.54%	2.77M 8.46%	-14.11M 610.04%	-138.98M 884.77%	-35.83M -
income tax expense	-1.43K -	-13.39K 839.86%	-16.86K 25.92%	-21.51K 27.54%	-4.06K 81.13%	-257.25K 6,237.79%	893K 447.13%	-6.58M 837.18%	1.23M -	3.90M 216.30%
net income	-1.18M -	-1.55M 31.04%	7.76M 599.99%	-19.45M 350.72%	3.02M 115.54%	2.77M 8.46%	-15.26M 651.60%	-107.15M 602.03%	-39.10M -	-3.90M 90.03%
weighted average shs out	11.68M -	43.13M 269.27%	43.13M 0%		43.13M -	43.13M 0%		107.56M -	122.08M -	122.08M 0%
weighted average shs out dil	11.68M -	43.13M 269.27%	43.13M 0%		43.13M -	43.13M 0%		107.56M -	122.08M -	122.08M 0%
eps	-0.10 -	-0.04 64%	0.18 600%		0.07 -	0.06 8.42%	-0.72 1,221.50%	-1 38.89%	-0.32 -	-0.03 90.03%
epsdiluted	-0.10 -	-0.04 64%	0.18 600%		0.07 -	0.06 8.42%	-0.72 1,221.50%	-1 38.89%	-0.32 -	-0.03 90.03%

NASDAQ:WALD

Waldencast

Last Close

3.47

26/07 20:00

Market Cap

456.93M

Beta: -

Volume Today

73.17K

Avg: 5.58K

PE Ratio

−2.75

PFCF: 366.52

Preview